The DNA Company launches genetic report for hormone and peptide wellness protocols

The DNA Company introduced DNA360™, a genetic report designed to give providers and patients more personalized insight into hormone therapy, peptide protocols and wellness planning. The Corona, California company says the report is built for educational use and draws on genetic markers tied to metabolism, inflammation, repair and other biological functions.

Why it matters: - DNA360™ targets a growing market for personalized health tools that aim to move wellness conversations beyond generic supplement and therapy advice. - The report is designed to help individuals and practitioners discuss hormone replacement therapy, peptide-based protocols, nutrition and lifestyle choices with more genetic context. - The DNA Company positions the product as an educational tool for data-informed decisions alongside qualified healthcare professionals.

What happened: - The DNA Company announced DNA360™, a new genetic report focused on biological factors relevant to hormone metabolism, cellular signaling and physiological responses. - The company says the report is intended to support discussions around hormone replacement therapy and peptide-based wellness protocols. - The announcement was made from Corona, California, on July 6, 2026.

The details: - DNA360™ evaluates genetic markers involved in hormone processing, detoxification, immune and inflammation regulation, cellular repair and metabolic function. - The report also covers vitamin and nutrient metabolism, methylation pathways, neurotransmitter function, energy production pathways, gut-related biological functions and cellular maintenance and repair pathways. - The company says the output provides educational insights that may help individuals and practitioners develop more personalized approaches to nutrition, lifestyle and wellness optimization. - Chief Science Officer Dr. Krista Kostroman, ND, said DNA360™ combines peer-reviewed scientific and clinical literature with insights from supporting clients and practitioners using functional genomics in clinical settings. - The DNA Company says aggregated observations from thousands of direct consultations helped shape interpretive models used in the report. - The company describes DNA360™ as a functional genetics platform intended to support more informed wellness conversations. - The DNA Company said interested readers can contact clientcare@thednacompany.com or follow the company on LinkedIn, YouTube, Instagram and Facebook. - The company says its broader testing portfolio includes DNA360™, DNA180, DNAging and DNA Gut 360, plus coaching programs, clinician consultations and educational resources through DNA University and The DNA Talks podcast. - The DNA Company says it is based in Corona, California, and is HIPAA compliant and CLIA certified. - The company’s disclaimer says DNA360™ is for educational and informational purposes only and is not intended to diagnose, treat, cure, prevent or mitigate disease.

Between the lines: - The launch reflects how genetic testing companies are trying to connect genomics with consumer-facing wellness categories such as HRT, peptides and food-based medicine. - The emphasis on clinical literature plus consultation data suggests the company wants DNA360™ to read as both evidence-informed and practice-tested. - The company’s framing also signals caution: DNA360™ is presented as a support tool, not a substitute for medical care.

What's next: - The DNA Company appears to be using the launch to expand practitioner and consumer interest in functional genomics-based wellness planning. - The company says DNA360™ should be used in partnership with qualified healthcare professionals, indicating the report is meant to feed into ongoing care conversations rather than replace them. - More information is available through the company’s direct contact channel and social accounts.